Scharf, Sebastian H.

Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome

Berry-Kravis, E. M., Lindemann, L., Jønch, A. E., Apostol, G., Bear, M. F., Carpenter, R. L., Crawley, J. N., Curie, A., Des Portes, V., Hossain, F., et al. (2018) · Nature Reviews Drug Discovery

Genetics and Neurodevelopmental DisordersNeuroscience and Neuropharmacology Research

Cited by 336

The involvement of FK506-binding protein 51 (FKBP5) in the behavioral and neuroendocrine effects of chronic social defeat stress

Hartmann, J., Wagner, K. V., Liebl, C., Scharf, S. H., Wang, X.-D., Wolf, M., Hausch, F., Rein, T., Schmidt, U., Touma, C., et al. (2012) · Neuropharmacology

Stress Responses and CortisolNeuropeptides and Animal Physiology

Cited by 224

Pharmacology of Basimglurant (RO4917523, RG7090), a Unique Metabotropic Glutamate Receptor 5 Negative Allosteric Modulator in Clinical Development for Depression

Lindemann, L., Porter, R. H., Scharf, S. H., Kuennecke, B., Bruns, A., von Kienlin, M., Harrison, A. C., Paehler, A., Funk, C., Gloge, A., et al. (2015) · The Journal of Pharmacology and Experimental Therapeutics

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 107

Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome

Scharf, S. H., Jaeschke, G., Wettstein, J. G., & Lindemann, L. (2015) · Current Opinion in Pharmacology

Genetics and Neurodevelopmental DisordersNeuroscience and Neuropharmacology Research

Cited by 106

Individual Stress Vulnerability Is Predicted by Short-Term Memory and AMPA Receptor Subunit Ratio in the Hippocampus

Schmidt, M. V., Trümbach, D., Weber, P., Wagner, K., Scharf, S. H., Liebl, C., Datson, N., Namendorf, C., Gerlach, T., Kühne, C., et al. (2010) · The Journal of Neuroscience

Neuroscience and Neuropharmacology ResearchStress Responses and Cortisol

Cited by 91